Nkarta, Inc. announced that Nadir Mahmood, PhD, has resigned his position as chief financial and business officer to serve as the chief executive officer of a private biotechnology company. Dr. Mahmood will remain with Nkarta until June 30, 2023, to ensure a smooth transition. Nkarta remains on track to announce updated results from its ongoing clinical trial of NKX101 in the second quarter of 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.27 USD | -0.48% | -15.47% | -5.23% |
May. 09 | Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 26 | Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.23% | 444M | |
+4.01% | 108B | |
+11.03% | 104B | |
+1.28% | 22.33B | |
-13.22% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.60% | 17.64B | |
+3.78% | 14.05B | |
+36.73% | 12.51B |
- Stock Market
- Equities
- NKTX Stock
- News Nkarta, Inc.
- Nkarta, Inc. Announces Resignation of Nadir Mahmood as Chief Financial and Business Officer